Brought to you by 
Mallinckrodt pays $1.2bn for hospital products company Cadence
10 Sep 2020
Executive Summary
Seven months after spinning off from Covidien Ltd. to become an independent, publicly traded entity focused on prescription opioids, Mallinckrodt PLC made its first major acquisition, paying $1.2bn ($14 per share, a 27% premium) for Cadence Pharmaceuticals Inc., a public hospital products company.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mallinckrodt pays $1.2bn for hospital products company Cadence
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice